6.
Su Y, Zhang X, Bidlingmaier S, Behrens C, Lee N, Liu B
. ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen. Cancer Res. 2020; 80(20):4552-4564.
PMC: 7572689.
DOI: 10.1158/0008-5472.CAN-20-1418.
View
7.
Schumacher T, Schreiber R
. Neoantigens in cancer immunotherapy. Science. 2015; 348(6230):69-74.
DOI: 10.1126/science.aaa4971.
View
8.
Jiang H, Dong J, Song K, Wang T, Huang W, Zhang J
. A novel allosteric site in casein kinase 2α discovered using combining bioinformatics and biochemistry methods. Acta Pharmacol Sin. 2017; 38(12):1691-1698.
PMC: 5719156.
DOI: 10.1038/aps.2017.55.
View
9.
Aizik L, Dror Y, Taussig D, Barzel A, Carmi Y, Wine Y
. Antibody Repertoire Analysis of Tumor-Infiltrating B Cells Reveals Distinct Signatures and Distributions Across Tissues. Front Immunol. 2021; 12:705381.
PMC: 8327180.
DOI: 10.3389/fimmu.2021.705381.
View
10.
Di Virgilio F, Adinolfi E
. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2016; 36(3):293-303.
PMC: 5269532.
DOI: 10.1038/onc.2016.206.
View
11.
Rodriguez F, Allende C, Allende J
. Protein kinase casein kinase 2 holoenzyme produced ectopically in human cells can be exported to the external side of the cellular membrane. Proc Natl Acad Sci U S A. 2005; 102(13):4718-23.
PMC: 555726.
DOI: 10.1073/pnas.0501074102.
View
12.
Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, OBrien S
. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70(24):10288-98.
DOI: 10.1158/0008-5472.CAN-10-1893.
View
13.
Cobbold M, De La Pena H, Norris A, Polefrone J, Qian J, English A
. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med. 2013; 5(203):203ra125.
PMC: 4071620.
DOI: 10.1126/scitranslmed.3006061.
View
14.
Zhang J, Xin L, Shan B, Chen W, Xie M, Yuen D
. PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. Mol Cell Proteomics. 2011; 11(4):M111.010587.
PMC: 3322562.
DOI: 10.1074/mcp.M111.010587.
View
15.
Tender G, Bertozzi C
. Bringing enzymes to the proximity party. RSC Chem Biol. 2023; 4(12):986-1002.
PMC: 10685825.
DOI: 10.1039/d3cb00084b.
View
16.
Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I
. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis. 2014; 5:e1135.
PMC: 3973218.
DOI: 10.1038/cddis.2014.109.
View
17.
Holton 3rd O, Black C, Parker R, Covell D, Barbet J, Sieber S
. Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies. J Immunol. 1987; 139(9):3041-9.
View
18.
Hu L, Zhang X, Jiang S, Tao L, Li Q, Zhu L
. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Clin Cancer Res. 2018; 25(4):1318-1330.
DOI: 10.1158/1078-0432.CCR-18-2297.
View
19.
Koerber J, Thomsen N, Hannigan B, DeGrado W, Wells J
. Nature-inspired design of motif-specific antibody scaffolds. Nat Biotechnol. 2013; 31(10):916-21.
PMC: 3795957.
DOI: 10.1038/nbt.2672.
View
20.
Doyle H, Zhou J, Wolff M, Harvey B, Roman R, Gee R
. Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J Biol Chem. 2006; 281(43):32676-83.
DOI: 10.1074/jbc.M604847200.
View